CVSA Stock Forecast & Price Target

Covista Inc. has demonstrated strong enrollment growth, with a 19% increase in new undergraduate enrollment in 2009 and an impressive rise of 18% and 38% in Chamberlain and Walden enrollments, respectively, projected between 2022 and 2025. The company's EBITDA margins have shown expansion in FY25/FY26E, leveraging operating gains from increased enrollment, while faster enrollment growth is expected to outpace the anticipated margin expansion, providing a positive outlook through FY29. Additionally, the successful acquisition of Walden in 2020 alongside a recent double-digit year-over-year increase in applications indicates a robust growth trajectory and increased interest in Covista's educational offerings.

The financial outlook for Covista Inc. appears negative due to a significant underperformance relative to the S&P, with a 22-point lag attributed to declining new student enrollments at Chamberlain, coupled with a falling EV/EBITDA multiple from approximately 12x to 8.6x. Additionally, the company's market share has decreased since peaking at around 10% in Fall 2010, largely due to increased regulatory scrutiny, negative publicity, and growing competition from traditional institutions now offering online programs. Finally, projected declines in cash conversion and free cash flow to EBITDA conversion rates indicate ongoing financial strain, with expected drops from 66% in FY26E to 58% in FY27E.